Advanced Magnetics seeks expanded Feridex use:
This article was originally published in Clinica
Advanced Magnetics has submitted a supplemental new drug application (sNDA) to the US FDA to expand the indications of its Feridex IV MRI contrast agent. The product is currently cleared to aid in the detection of liver lesions, but the Cambridge, Massachusetts company seeks approval to use the agent for characterising the lesions as benign or metastatic. In addition, the company would like a more convenient, rapid infusion, dosing regimen.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.